Get started
Author

Mariana Carbini

Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial
2024 · Jürgen Wolf, Maximilian Hochmair, et al. · The Lancet Oncology · 86
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non–Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial
2023 · Edward B. Garon, Shun Lu, et al. · Journal of Clinical Oncology · 85
Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition
2017 · Angela Pang, Mariana Carbini, et al. · Journal of Clinical Oncology · 80
Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.
2021 · Juergen Wolf, Edward B. Garon, et al. · Journal of Clinical Oncology · 25
Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults
2016 · Angela Pang, Mariana Carbini, et al. · JAMA Oncology · 23
A Method to Summarize Toxicity in Cancer Randomized Clinical Trials
2018 · Mariana Carbini, Mayte Suárez-Fariñas, et al. · Clinical Cancer Research · 20
PDF
LBA49 CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)
2022 · E.B. Garon, S. Lu, et al. · Annals of Oncology · 12
PSMA-delay castration (DC): An open-label, multicenter, randomized phase 3 study of [ 177 Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer (OMPC).
2025 · Alton Oliver Sartor, Ana Ponce Kiess, et al. · Journal of Clinical Oncology · 11
PDF
Capmatinib in MET exon 14-mutated advanced NSCLC: updated results from the GEOMETRY mono-1 study.
2022 · J Wolf, E B Garon, et al. · Pneumologie · 10
Pegylated liposomal doxorubicin (PLD) as an active treatment option for desmoid tumor (DT) patients.
2016 · Angela Pang, Daniela Venancio Gouveia Macedo, et al. · Journal of Clinical Oncology · 10
26P Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): Updated results from GEOMETRY mono-1
2022 · J. Wolf, E.B. Garon, et al. · Annals of Oncology · 9
Phase 1b/2 study of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated non-small cell lung cancer who received prior therapy: Final overall survival and safety.
2021 · Yi-Long Wu, Li Zhang, et al. · Journal of Clinical Oncology · 5
1256P Capmatinib safety update in MET dysregulated NSCLC from the GEOMETRY mono-1 trial
2021 · R.S. Heist, E.B. Garon, et al. · Annals of Oncology · 4
PDF
Dynamic path analysis for exploring treatment effect mediation processes in clinical trials with time‐to‐event endpoints
2024 · Matthias Kormaksson, Markus Reiner Lange, et al. · Statistics in Medicine · 2
P47.17 Capmatinib vs Docetaxel in Pretreated Patients With MET Exon 14 Skipping–mutated Stage IIIB/IIIC or IV NSCLC (GeoMETry-III)
2021 · P. Souquet, S. Kim, et al. · Journal of Thoracic Oncology · 2
PDF
2537eTiP PSMACare trial-in-progress: a phase II trial of [177Lu]Lu-PSMA-617 with or without ARPI in patients with PSMA-positive non-metastatic castration-resistant prostate cancer
2025 · F. Saad, J. Puente, et al. · Annals of Oncology
Supp Figure 2 from A Method to Summarize Toxicity in Cancer Randomized Clinical Trials
2023 · Mariana Carbini, Mayte Suárez-Fariñas, et al.
Suppl Table 2 from A Method to Summarize Toxicity in Cancer Randomized Clinical Trials
2023 · Mariana Carbini, Mayte Suárez-Fariñas, et al.
Suppl Table 3 from A Method to Summarize Toxicity in Cancer Randomized Clinical Trials
2023 · Mariana Carbini, Mayte Suárez-Fariñas, et al.
Suppl Table 1 from A Method to Summarize Toxicity in Cancer Randomized Clinical Trials
2023 · Mariana Carbini, Mayte Suárez-Fariñas, et al.
Supp Figure 1 from A Method to Summarize Toxicity in Cancer Randomized Clinical Trials
2023 · Mariana Carbini, Mayte Suárez-Fariñas, et al.
Data from A Method to Summarize Toxicity in Cancer Randomized Clinical Trials
2023 · Mariana Carbini, Mayte Suárez-Fariñas, et al.
Data from A Method to Summarize Toxicity in Cancer Randomized Clinical Trials
2023 · Mariana Carbini, Mayte Suárez-Fariñas, et al.
Supplemental legend from A Method to Summarize Toxicity in Cancer Randomized Clinical Trials
2023 · Mariana Carbini, Mayte Suárez-Fariñas, et al.
Supp Figure 2 from A Method to Summarize Toxicity in Cancer Randomized Clinical Trials
2023 · Mariana Carbini, Mayte Suárez-Fariñas, et al.
Works count: 34
Citation count: 384
H-index: 10
I10-index: 10
Year
Topic
Type